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Context: The relationship between thyroid function and bone mineral density (BMD) is contro-
versial. Existing studiesare conflictingandconfoundedbydifferences in studydesign, small patient
numbers, and sparse prospective data.
Objective: We hypothesized that variation across the normal range of thyroid status in healthy
postmenopausal women is associated with differences in BMD and fracture susceptibility.
Design: The Osteoporosis and Ultrasound Study (OPUS) is a 6-yr prospective study of fracture-
related factors.
Setting: We studied a population-based cohort from five European cities.
Participants: A total of 2374 postmenopausal women participated. Subjects with thyroid disease
and nonthyroidal illness and those receiving drugs affecting thyroid status or bone metabolism
were excluded, leaving a study population of 1278 healthy euthyroid postmenopausal women.
Interventions: There were no interventions.
Main Outcome Measures: We measured free T4 (fT4) (picomoles/liter), free T3 (fT3) (picomoles/
liter), TSH (milliunits/liter), bone turnover markers, BMD, and vertebral, hip, and nonvertebral
fractures.
Results: Higher fT4 (0.091; P 0.004) and fT3 (0.087; P 0.005) were associated with
lowerBMDat thehip, andhigher fT4wasassociatedwith increasingbone loss at thehip (0.09;
P 0.015). After adjustment for age, bodymass index, and BMD, the risk of nonvertebral fracture
was increasedby20%(P0.002)and33%(P0.006) inwomenwithhigher fT4or fT3, respectively,
whereas higher TSH was protective and the risk was reduced by 35% (P  0.028). There were
independentassociationsbetweenfT3andpulse rate (0.080;P0.006), increasedgrip strength
(  0.171; P0.001), and better balance (  0.099; P  0.001), indicating that the relationship
between thyroid status and fracture risk is complex.
Conclusions: Physiological variation in normal thyroid status is related to BMD and nonvertebral
fracture. (J Clin Endocrinol Metab 95: 0000–0000, 2010)
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Low bonemineral density (BMD), prior or parental his-tory of fracture, low body mass index (BMI), use of
glucocorticoids, smoking, excessive alcohol consumption,
untreated thyrotoxicosis, and other factors increase sus-
ceptibility to osteoporosis. Even subclinical hyperthyroid-
ism, defined by a suppressed TSH level in the presence of
normal thyroid hormone concentrations, is associated
with fracture (1, 2), and treatment with T4 at doses that
suppress TSH is associated with increased bone turnover
and lowBMD inpostmenopausalwomen (3, 4). The prev-
alence of thyroid disease increaseswith age: 3%ofwomen
over50 receiveT4, andmore than20%areovertreated (5).
Subclinical hyperthyroidism affects a further 1.5% of
women over 60, and its prevalence increases with age (6).
Nevertheless, the role of thyroid hormones in the patho-
genesis of osteoporosis remains uncertain (3, 7).
Longitudinal differences in free T3 (fT3), free T4 (fT4),
andTSH in healthy individuals fluctuate by less than 50%
of the population reference range (8). Each person has a
unique hypothalamic-pituitary-thyroid (HPT) axis set-
point, implying that tissue thyroid hormone sensitivity
varies between individuals. Data from the UKAdult Twin
Registry estimate heritability for fT3 concentration at
23%, fT4 at 39%, andTSHat 65%(9),whereas estimates
from Denmark were higher (10). A genome-wide screen
identified eight quantitative trait loci linked to circulating
fT3, fT4, and TSH levels, indicating that thyroid status is
inherited as a complex trait (11), and genome-wide asso-
ciation studies demonstrate thatmany signaling pathways
influence BMD and fracture susceptibility (12).
We hypothesized that variation across the normal
range of thyroid status in healthy euthyroid postmeno-
pausal women is associated with differences in BMD and
fracture susceptibility.
Subjects and Methods
Osteoporosis and Ultrasound Study (OPUS)
OPUS is a prospective study of postmenopausal women re-
cruited between April 1999 and April 2001 from five European
centers (13). Investigations were approved at each institution
according to the Declaration of Helsinki. Written consent was
obtained from all subjects. Each center recruited approximately
100 women between 20 and 40 yr of age to calculate adjusted
T-scores for BMD and approximately 500 postmenopausal
women comprising 100 individuals in each 5-yr age band be-
tween 55 and 80. Ninety-nine percent of subjects were of white
ethnicity. Individuals were excluded because of inability to un-
dergo bone densitometry or perform specified investigations or
because of cognitive limitations. A total of 566 premenopausal
and 2374 postmenopausal women participated. Subjects com-
pleted a modified version of the European Vertebral Osteopo-
rosis Study risk factor questionnaire (14, 15).
Biochemical measurements
Nonfasting samples were taken between 1200 and 1500 h,
and serum was stored at 75 C. TSH, fT4, and fT3 were mea-
sured on a single automated analyzer using the ARCHITECT
System (Abbott ARCHITECT i2000; Abbott Laboratories,
Maidenhead, UK). This fT4 assay performs reliably compared
with equilibrium dialysis, the gold standard method (16). All
sampleswere analyzedwithin a 3-month period, and coefficients
of variation were: TSH, 4.0%; fT3, 10.0%; and fT4,
10.4%.
Serum type I collagen C-terminal telopeptide (sCTX), a
bone resorption marker, and procollagen type I N-terminal
propeptide (PINP) and osteocalcin (OC), bone formation mark-
ers, were measured on an Elecsys 2010 (Roche Diagnostics,
Mannheim,Germany). Blood sampleswere collected at the same
time of day to mitigate effects of diurnal variation. Urinary N-
terminal telopeptide of type I collagen (uNTX), a bone resorp-
tion marker, and urinary creatinine were measured using dry
slidemethods (Ortho-Clinical Diagnostics, Rochester, NY). Co-
efficients of variation were 8.1% (sCTX), 1.1% (PINP),
1.3% (OC), and 1.7% (uNTX). uNTX was expressed as a
ratio to creatinine excretion (uNTX/Cr).
Physical measurements
Dual-energy x-ray absorptiometry scans were performed in
posteroanterior projection (Hologic QDR-4500; Hologic Inc.,
Bedford, MA) in Kiel, Germany; Paris; and Sheffield, United
Kingdom; or in anteroposterior projection (Lunar Expert de-
vices; GE Lunar Corp.,Madison,WI) in Aberdeen, UnitedKing-
dom, and Berlin (13, 15, 17, 18). Results were corrected for
longitudinal changes (based on daily measurements of the Eu-
ropean Spine Phantom) (19) and for differences among centers
(20). Results of the samebrandwere adjusted according to cross-
calibration phantom data, whereas results of different brands
were standardized by expressing dual-energy x-ray absorptiom-
etry results as standardized BMD (21, 22). For lumbar spine, the
totalBMDofvertebraeL2–L4was evaluated, andmeasurements
were performed only in women who had not sustained a verte-
bral fracture. Subjects in whom fewer than two vertebrae could
be evaluated were excluded. For the hip, total BMD of the prox-
imal femur was determined. Change in BMD was calculated as
BMD at follow-up minus BMD at entry.
Lateral spine radiographs were obtained at study entry and
after 6.1  0.6 yr. Incident fractures were defined in vertebrae
that sustained a deformity of greater than 20% in the anterior,
middle, or posterior height ratio (13, 18). Hip fractures were
ascertained by questionnaire after 6-yr follow-up and validated
by analysis of medical records and imaging. Incident nonverte-
bral fractures were similarly recorded and validated. Grip
strength was determined using a dynamometer (Takei Scientific,
Tokyo, Japan). Twomeasurementswere taken in eachhand, and
the mean was calculated. Subjects were asked to walk backward
without deviating along a 5-m line, and the point of deviation
was scored in 10-cm intervals to assess balance.
Study population
To determine reference intervals for normal euthyroid status,
fT3, fT4, and TSH ranges were calculated for each decade of age
(55–65, 65–75, 75) in 1754 healthy euthyroid postmeno-
pausal women after exclusion of individuals with thyroid dis-
ease, chronic illness, other evidence of the sick euthyroid syn-
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drome, or those receiving drugs affecting thyroid function. The
2.5th and 97.5th percentiles were calculated for fT4 and fT3.
TSH values were ranked, and 2.5th and 97.5th percentiles were
calculated. To analyze relationships between fT3, fT4, and TSH
levels and bone parameters, a further 476 individuals receiving
drugs that interfere with bone metabolism were excluded, re-
sulting in a final analysis population of 1278. This rigorously
defined group of healthy euthyroid postmenopausal women not
receiving drugs affecting bone metabolism represents a normal
healthy postmenopausal European Caucasian population.
Statistics
Analyses were performed using SPSS v.14 (SPSS Inc., Chi-
cago, IL) or GraphPad Prism v.5 (GraphPad Software, Inc., San
Diego,CA).Datawere assessed for normal distributionusing the
Kolmogorov-Smirnov test, and nonparametric variables under-
went logarithmic transformation, afterwhich TSH, sCTX, and
uNTX/Cr datasets remained skewed.
fT4 and fT3 levels were grouped into quintiles and one-way
between-groups ANOVA was conducted to explore relation-
ships between fT4 or fT3 and BMD, bone formation markers,
pulse rate, grip strength, and balance. Comparisons between
highest and lowest quintiles were performed using Tukey’s post
hoc test. Comparisons with bone resorption markers were per-
formed using Kruskal-Wallis (K-W) and Dunn’s post hoc tests.
TSH data were analyzed by Mann-Whitney U (M-WU) to com-
pare effects ofTSH levels below0.5mU/liter
with levels of at least 0.5 mU/liter.
Odds ratios (ORs) for vertebral fracture in
relation to fT4, fT3, and TSH were deter-
minedusingunadjustedandadjusted (for age,
BMI, and BMD) logistic regression. Incident
nonvertebral fracture (including hip fracture)
risk was determined by Cox proportional-
hazards modeling. The independent variable
unitofanalysis forORandhazardsratio (HR)
was 1 pmol/liter for fT4 and fT3 and 1 mU/
liter for TSH. To conform to regression anal-
yses, datawerealsopresentedper SD change in
fT4, fT3, and TSH. Analysis of covariance
wasusedtocomparefT4levels inwomenwith
an incident hip fracture to those without.
Stepwiseadjustedregressionanalysisof re-
lationships between thyroid status and BMD,
bone turnover, pulse rate, grip strength, and
balance was performed after adjustment for
age or BMI, smoking, and age.
Results
Thyroid function in healthy
postmenopausal women
To define a healthy euthyroid population, subjects re-
ceiving T4 (n 237), antiepileptics (n 19), or glucocor-
ticoids (n 76); those with renal disease (n 54), cancer
(n217), orovert thyroiddisease (TSH10mU/liter and
fT4  9 pmol/liter; or TSH  10 mU/liter and fT3  2.5
pmol/liter; or TSH 0.1mU/liter and fT3 6 pmol/liter)
(n  20); and individuals with sick euthyroid syndrome,
defined as fT3 less than 2.5 pmol/liter plus one or more of
malabsorption, rheumatoid arthritis, bone disease other
than osteoarthritis, psoriasis, or asthma (n  63), were
excluded. Several subjects fulfilled two or more criteria,
resulting in exclusion of 620 individuals to obtain a pop-
ulation of 1754 healthy euthyroid postmenopausal
women (Fig. 1), in which reference intervals for normal
thyroid function were defined (Table 1). There were no
differences in smoking, alcohol consumption, prevalence
of osteoarthritis, or family history of fracture between this
healthy euthyroid group and the total population. There
was apositive correlationbetween fT4and fT3 (r0.404;
P  0.01), whereas fT4 and fT3 correlated negatively
with TSH (rho  0.183, P  0.001; and rho 
0.050, P 0.05, respectively). fT4 and fT3 increased
FIG. 1. Exclusion criteria to define populations of healthy euthyroid postmenopausal women
and those women not receiving drugs affecting bone metabolism.
TABLE 1. Age-related reference ranges for thyroid function tests
Analyte All women > 55 yr old 55–65 yr 66–75 yr >75 yr
TSH (mU/liter) 0.13–3.48 0.14–3.48 0.16–3.48 0.04–3.80
fT4 (pmol/liter) 9.15–16.99 8.87–16.89 9.24–16.91 9.61–17.12
fT3 (pmol/liter) 2.16–5.29 2.07–5.28 2.22–5.32 2.24–5.31
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with age (F  21.26, P  0.0001; F  3.482, P  0.05,
respectively), whereas TSH remained constant (K-W,
0.0003; P  0.999).
Analysis population
To determine relationships between thyroid status and
bone parameters, individuals receiving drugs affecting
bonemetabolism (n476)were excluded to define a final
analysis groupof 1278healthy euthyroidpostmenopausal
women not receiving drugs affecting bone metabolism
(Fig. 1 and Table 2).
In the analysis population, the following data were un-
available: lumbar spine BMD at entry into the study in six
individuals, hip BMD at entry in 10, lumbar spine BMD
after 6-yr follow-up in 489, and hip BMD at follow-up in
486. This resulted in a total of 788women inwhich paired
BMDdatawere available. TSHvalueswere unavailable in
74 individuals, fT4 in 66, fT3 in 65, pulse rate in 34, grip
strength in 193, balance in 38, OC in 61, PINP in 61,
sCTX in 61, and uNTX/Cr in 64. Taken together, a com-
plete set of data were available in 593 women (Supple-
mental Table 1, published on The Endocrine Society’s
JournalsOnlineweb site at http://jcem.endojournals.org).
Subjects in whom specific data were missing were ex-
cluded before statistical analysis.
Lower BMD in women with higher fT4 and fT3
Individuals with fT4 levels in the highest quintile had
lower BMD thanwomenwith fT4 in the lowest quintile at
both lumbar spine and hip at entry into the study (lumbar
spine F 2.29, P 0.050; hip F 2.96, P 0.021) and
at the hip after 6-yr follow-up (F  4.32, P  0.041).
Individuals with fT3 in the highest quintile had lower
BMDat the hip after 6-yr follow-up (F2.68,P0.045).
The mean BMD values of women with fT4 and fT3 levels
in the lowest and highest quintiles are included in Supple-
mental Table 2. Figure 2 shows quintile plots relating hip
and lumbar spine BMD at study entry and after 6-yr fol-
low-upandmeanchange inBMDto fT4 levels.Theseplots
illustrate the inverse relationship between hip BMD and
fT4 across the normal range of fT4 concentration. There
was no relationship between TSH and BMD.
Increased risk of nonvertebral fracture in women
with higher fT4 and fT3
There were 52 incident vertebral fractures in 44 indi-
viduals and 86 nonvertebral fractures, including seven hip
fractures in seven individuals, among the 1278 healthy
FIG. 2. Graphs showing hip (A) and lumbar spine (B) mean BMD 
95% confidence interval (CI) at the time of entry into the study and
after 6-yr follow-up in relation to quintiles of fT4 concentration. C,
Mean change in BMD  95% CI in relation to fT4.
TABLE 2. Baseline characteristics
Healthy euthyroid
postmenopausal women,
no bone-modifying drugs
n 1278
Age (yr) 68  7
BMI (kg/m2) 27.2  4.7
Years since menopause 18.8  9.1
TSH (mU/liter) 0.88 (range, 0.15–3.64)
fT4 (pmol/liter) 12.9  2.0
fT3 (pmol/liter) 3.7  0.8
Lumbar spine BMD (mg/cm2) 1028  180
Hip BMD (mg/cm2) 839  131
OC (ng/ml) 26.0  10.6
PINP (ng/ml) 55.0  20.0
sCTX (ng/ml) 0.271  0.248
uNTX/Cr (nM/mM) 56.6  31.0
Grip strength (kg) 18  5
Balance (m) 3.2  2.0
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euthyroid postmenopausal women not receiving drugs af-
fecting bone metabolism in whom data were available
(Supplemental Table 1). Unadjusted and adjusted logistic
regression indicated that fT4, fT3, and TSH levels were
not related to vertebral fracture (Table 3).
Unadjusted Cox proportional hazards analysis re-
vealed that the risk of incident nonvertebral fracture (in-
cluding hip fracture) was increased by 18 and 34% in
women with higher fT4 and fT3, respectively. After ad-
justment for age, BMI, and BMD, the risk of nonvertebral
fracture was increased by 20 and 33% in women with
higher fT4 or fT3, whereas in women with higher TSH,
this risk was reduced by 35% (Table 3). Separate analysis
of hip fractures byCox proportional hazardswas not pos-
sible because only seven were recorded. Nevertheless,
women with an incident hip fracture had higher fT4 than
women without (14.4  2.2 vs. 12.7  1.9 pmol/liter,
analysis of covariance; F 4.87; P 0.03). After adjust-
ment for BMI, this relationship did not change (F 4.87;
P  0.03), but after adjustment for age the relationship
was not significant (F  3.25; P  0.072).
Thyroid status is associated with pulse rate, grip
strength, balance, and bone turnover
Pulse rate, grip strength, balance, and bone turnover
markers were investigated as possible factors underlying
associations between thyroid status and bone parameters.
Individuals with fT3 in the highest quintile had increased
TABLE 3. Relationship between thyroid function tests and fracture
Logistic regression model Cox proportional hazards model
OR (95% CI)
P
HR (95% CI)
PPer unit change Per SD change Per unit change Per SD change
Prevalent vertebral
fracture
1.08 (0.99–1.17) 1.15 (0.98–1.35) 0.087 fT4 Unadjusted
Incident vertebral
fracture
0.91 (0.76–1.10) 0.84 (0.59–1.20) 0.336 fT4 Unadjusted
Incident nonvertebral
fracture
0.82 (0.72–0.93) 0.69 (0.54–0.87) 0.002 fT4 Unadjusted
Prevalent vertebral
fracture
0.92 (0.75–1.12) 0.94 (0.79–1.10) 0.407 fT3 Unadjusted
Incident vertebral
fracture
1.06 (0.69–1.62) 1.05 (0.74–1.47) 0.794 fT3 Unadjusted
Incident nonvertebral
fracture
0.66 (0.51–0.86) 0.72 (0.58–0.86) 0.002 fT3 Unadjusted
Prevalent vertebral
fracture
1.04 (0.92–1.17) 1.03 (0.94–1.21) 0.569 TSH Unadjusted
Incident vertebral
fracture
1.20 (0.86–1.68) 1.24 (0.80–1.86) 0.286 TSH Unadjusted
Incident nonvertebral
fracture
1.18 (0.93–1.51) 1.22 (0.92–1.64) 0.167 TSH Unadjusted
Prevalent vertebral
fracture
1.03 (0.94–1.12) 1.06 (0.90–1.24) 0.581 fT4 Adjusted for age, BMI
and lumbar spine
BMD
Incident vertebral
fracture
0.91 (0.75–1.10) 0.84 (0.58–1.20) 0.318 fT4 Adjusted for age, BMI
and lumbar spine
BMD
Incident nonvertebral
fracture
0.80 (0.70–0.92) 0.65 (0.51–0.85) 0.002 fT4 Adjusted for age, BMI
and lumbar spine
BMD
Prevalent vertebral
fracture
0.84 (0.68–1.03) 0.89 (0.73–1.02) 0.099 fT3 Adjusted for age, BMI
and lumbar spine
BMD
Incident vertebral
fracture
1.10 (0.70–1.70) 1.08 (0.75–1.53) 0.685 fT3 Adjusted for age, BMI
and lumbar spine
BMD
Incident nonvertebral
fracture
0.67 (0.51–0.89) 0.73 (0.58–0.91) 0.006 fT3 Adjusted for age, BMI
and lumbar spine
BMD
Prevalent vertebral
fracture
1.02 (0.90–1.15) 1.02 (0.88–1.18) 0.775 TSH Adjusted for age, BMI
and lumbar spine
BMD
Incident vertebral
fracture
1.27 (0.91–1.77) 1.33 (0.89–1.98) 0.167 TSH Adjusted for age, BMI
and lumbar spine
BMD
Incident nonvertebral
fracture
1.35 (1.03–1.76) 1.43 (1.04–1.97) 0.028 TSH Adjusted for age, BMI
and lumbar spine
BMD
Statistically significant results are shown in bold. Units of measure are: fT4, pmol/liter; fT3, pmol/liter; and TSH, mU/liter. CI, Confidence interval.
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grip strength (F  7.68; P  0.001), better balance (F 
4.49; P  0.023), and higher uNTX/Cr (K-W  11.21;
P  0.01). Women with TSH less than 0.5 mU/liter had
better balance (M-WU  97,190; P  0.036) and in-
creased bone turnover (OC,M-WU 97,840, P 0.005;
PINP, M-WU  101,400, P  0.039; sCTX, M-WU 
100,700, P  0.027; uNTX/Cr, M-WU  87,880, P 
0.001) compared with women with TSH of at least 0.5
mU/liter. After adjusted regression analysis, however,
TSH was not associated with bone turnover (see below
and Table 4).
Adjusted regression
Stepwise regression was performed to investigate rela-
tionships between thyroid hormones and BMD, pulse
rate, grip strength, balance, andmarkers of bone turnover.
After adjustment for age, higher fT4 was associated
with lower hip BMD at study entry and after 6-yr follow-
up, and with increased bone loss at the hip after 6-yr fol-
low-up (Supplemental Table 3). Higher fT4 was also as-
sociatedwith increased grip strength.After adjustment for
BMI, smoking, and age, higher fT4 was still associated
with reduced BMD and bone loss at the hip and with
increased grip strength (Table 4).
After adjustment for age, higher fT3 was associated
with lower hip BMDafter 6-yr follow-up.Higher fT3was
also associated with higher pulse rate, increased grip
strength, and better balance, and with reduced bone loss
at the lumbar spine and lower levels of sCTX (Supple-
mentalTable 3). These associations remained after further
adjustment for BMI and smoking (Table 4).
TSHwas not associatedwith alterations in BMD, bone
turnover markers, or other extraskeletal parameters.
Discussion
These studies demonstrate that physiological variation in
thyroid status is related to BMD and fracture in healthy
euthyroid postmenopausal women. Higher fT4 and fT3
were associated with reduced BMD, and higher fT4 was
associated with increased bone loss at the hip. Cox pro-
portional hazards analysis revealed an increased risk of
nonvertebral fracture in women with higher fT4 and fT3
and protection from nonvertebral fracture with higher
TSH. Thus, thyroid status within the upper normal range
was associated with reduced BMD at the hip and an in-
creased risk of nonvertebral fracture.
Although there was increased loss of hip BMD with
increasing fT4 and fT3 levels, there was reduced loss of
BMD at the lumbar spine with increasing fT3 and no as-
sociation between vertebral BMDand fT4. These findings
are consistent with the lack of relationship between fT4,
fT3, andvertebral fracture.The reason for thediscrepancy
between hip and lumbar spine is not known, although
TABLE 4. Relationship between thyroid function tests, BMD, bone turnover, and extraskeletal parameters
fT4 (pmol/liter) fT3 (pmol/liter) TSH (mU/liter)
Model
R2
 coefficient (95% CI)
(lower, upper, per SD
change) P
Model
R2
 coefficient (95% CI)
(lower, upper, per SD
change) P
Model
R2
 coefficient (95% CI)
(lower, upper, per SD
change) P
BMD
At study entry
Lumbar spine
BMD
0.126 0.042 (9.059, 1.407) 0.152 0.126 0.043 (21.127, 3.061) 0.143 0.127 0.050 (15.552, 1.040) 0.086
Hip BMD 0.293 0.051 (7.299, 0.174) 0.040 0.292 0.042 (15.779, 1.121) 0.089 0.290 0.014 (7.700, 4.144) 0.556
At 6 yr follow-up
Lumbar spine
BMD
0.128 0.054 (11.936, 1.870) 0.153 0.125 0.026 (10.173, 21.269) 0.489 0.126 0.040 (24.494, 7.231) 0.286
Hip BMD 0.304 0.091 (10.044, 1.976) 0.004 0.304 0.087 (23.439, 4.313) 0.005 0.298 0.04 (2.233, 11.222) 0.190
Change in
lumbar
spine BMD
0.113 0.021 (2.038, 3.609) 0.585 0.128 0.123 (4.227, 16.967) 0.001 0.113 0.004 (6.833, 6.137) 0.916
Change in hip
BMD
0.027 0.090 (4.069, 0.439) 0.015 0.023 0.053 (7.543, 1.082) 0.142 0.024 0.067 (0.177, 5.852) 0.065
Bone turnover
OC 0.032 0.029 (0.457, 0.151) 0.322 0.032 0.009 (0.831, 0.611) 0.764 0.035 0.054 (0.991, 0.017) 0.058
PINP 0.017 0.006 (0.517, 0.639) 0.835 0.017 0.008 (1.570, 1.171) 0.776 0.018 0.038 (1.612, 0.307) 0.182
sCTX 0.020 0.022 (0.004, 0.010) 0.443 0.023 0.060 (0.035, 0.001) 0.037 0.021 0.035 (0.019, 0.005) 0.225
uNTX/Cr 0.017 0.033 (0.399, 1.424) 0.270 0.018 0.049 (0.330, 3.988) 0.097 0.016 0.014 (1.888, 1.140) 0.628
Extraskeletal
parameters
At study entry
Pulse rate 0.022 0.034 (0.121, 0.457) 0.253 0.027 0.08 (0.285, 1.652) 0.006 0.021 0.020 (0.652, 0.309) 0.483
Grip strength 0.097 0.074 (0.040, 0.362) 0.014 0.121 0.171 (0.734, 1.488) <0.001 0.094 0.042 (0.458, 0.079) 0.165
Balance 0.109 0.052 (0.003, 0.110) 0.064 0.116 0.099 (0.111, 0.377) <0.001 0.106 0.009 (0.019, 0.079) 0.753
Statistically significant results are shown in bold. Data are adjusted for age, BMI, and smoking. CI, Confidence interval.
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animal studies reveal that decreases in BMD after treatment
with thyroid hormones occur preferentially at the hip (23).
After adjusted regression, relationships between fT4 or
fT3 and BMDwere not independent of TSH or each other
but were consistent with the positive correlation between
fT4 and fT3 and their inverse relationship with TSH. This
interaction results from the physiological regulation of
thyroid status mediated by the HPT axis, in which fT3,
fT4, and TSH are dependent variables. Because of the cor-
relation between fT4 and fT3, their interactionwith TSH,
and the results of regression analyses in which indepen-
dent relationships between fT3, fT4, or TSH and bone
parameters were lacking, effects of T3, T4, or TSH on the
skeleton cannot be separated. Indeed, because skeletal re-
sponses to thyroidhormones andTSHare interdependent,
it is impossible to resolve this issue in any study of healthy
euthyroid individuals in whom the HPT axis maintains
thyroid hormones and TSH in a physiological reciprocal
relationship (24).
Nevertheless, independent associations between fT3
and pulse rate, grip strength, and balance were also iden-
tified. These findings reveal novel interactions between
fT3 and the cardiovascular and neuromuscular systems
that could modify the relationship between thyroid status
and bone maintenance and complicate analysis of the
mechanisms by which the HPT axis regulates BMD and
fracture susceptibility (2).
As indicated, the current study identified the well-
known inverse relationship between thyroid hormones
and TSH as well as the positive association between fT4
and fT3. Interestingly, fT4 and fT3 levels increased with
age, but TSH was unchanged. This appears surprising
given that theWhickhamstudy in theUnitedKingdomand
the Framingham, National Health and Nutrition Exami-
nation Survey (NHANES) III, and Colorado studies in the
United States indicated that the frequency of hypothyroid-
ism increases with age (25–28). By contrast, Austrian and
Danish studies have shown that hyperthyroidism is more
common in the elderly. This discrepancy is thought to
result from an increased prevalence of thyrotoxicosis in
the elderly in countrieswith low iodine supply,whereas an
increased prevalence of hypothyroidism occurs in iodine-
sufficient countries (29–31). Importantly, large popula-
tion studies are designed to characterize the extent of thy-
roid dysfunction in the population rather than to identify
a healthy euthyroid population based on stringent exclu-
sion criteria as in the current study. Indeed, there is little
information about thyroid status in healthy euthyroid el-
derly individuals.Reduced synthesis and secretionofTRH
and TSH appear to result in TSH levels in the low-normal
range, and reduced thyroidal secretion of T3 and T4 is
compensatedbydecreased clearanceof thyroidhormones.
The most extensive reviews of the subject suggest that in
healthy elderly subjects, fT4 levels are normal, whereas
TSH levels are lower than in younger individuals. fT3may
be lower in the very elderly, but this finding has been dis-
puted (31, 32). To our knowledge, no studies have exam-
ined healthy euthyroid postmenopausal women specifi-
cally. Thus, the small increases in fT4 and fT3 with age
along with maintenance of stable TSH concentrations in
the OPUS population may reflect the normal situation in
healthy euthyroidpostmenopausalwomen. It is important
to note, however, that differences in local iodine suffi-
ciency may complicate overall thyroid status in the OPUS
population.
The current study is the largest, most rigorous investi-
gation of the relationship between normal thyroid status
and BMD and the only prospective analysis relating eu-
thyroid status to incident fracture. Previous studies are
confounded by differences in experimental design, and
none included measurement of T3. Two prospective stud-
ies investigated relationships between thyroid status,
BMD, and fracture. Van der Deure et al. (33) followed
1151 men and women age 55 yr or older for 8.7 yr and
included subjects with nonthyroidal illness and individu-
als receiving drugs affecting bone metabolism. BMD cor-
related inversely with fT4 and positively with TSH, al-
though the relationship with fT4 was stronger. No
associations between fT4 or TSH and fracture were iden-
tified (33). Bauer et al. (1, 34) measured TSH in 600
womenmore than 65 yr of age from a population of 9704
that included subjects with thyroid disease and nonthy-
roidal illness and individuals receiving drugs affecting
bone metabolism. Women with suppressed TSH had an
increased risk of hip and vertebral fracture during 3.7 yr
of follow-up, although no relationship between TSH and
BMD was observed in a sample of 458 women from the
same population followed for 5.7 yr (1, 34). Two cross-
sectional studies investigated relationshipsbetweeneuthy-
roid status and BMD. In the NHANES III study, which
included postmenopausal women from diverse ethnic
groups receiving T4 or drugs affecting bone metabolism,
BMD increased as TSH increased within the reference
range and osteopenia or osteoporosis occurred more fre-
quently in women with low-normal TSH. No relation-
ships between total T4 andBMDwere identified (35). Kim
et al. (36) studied 959 postmenopausal Korean women
who were considerably younger than OPUS subjects.
WomenwithTSHbetween0.5 and1.1mU/liter had lower
BMD compared with individuals with TSH between 2.8
and 5.0 mU/liter, but no relationship between fT4 and
BMD was seen (36).
The inverse relationship between fT4 and BMD in the
current study is consistent with Van der Deure et al. (33),
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but differs from NHANES III and Kim et al. (35, 36) in
which BMD correlated with TSH. In rodents, TSH has
been proposed to inhibit bone turnover directly, and TSH
deficiency was suggested to cause high bone turnover os-
teoporosis in hyperthyroidism (37). Although skeletal
consequences of thyrotoxicosis could result fromTSHde-
ficiency or thyroid hormone excess, the current study and
previous studies cannot determine their relative impor-
tance in skeletal homeostasis because the physiological
reciprocal relationship between thyroid hormones and
TSH remains intact in all subjects studied, as discussed
earlier (24).
Nevertheless, all available studies are consistent with
our finding that thyroid status at the “hyperthyroid” end
of the normal range is associated with lower BMD and
increased risk of nonvertebral fracture. Furthermore,
studies of bone loss in postmenopausal women treated for
subclinical hyperthyroidism (38) or receiving T4 (4) also
reveal thatmild degrees of hyperthyroidism are associated
with reduced BMD. These studies additionally suggest
that thyroid status and BMD are related continuous vari-
ables because optimization of euthyroid status in post-
menopausal women with mild or subclinical hyperthy-
roidism reversed bone loss (4, 38). In further agreement,
Grimnes et al. (39) studied 993 postmenopausal women
and 968 men from Tromso and showed that individuals
with TSH below the 2.5th percentile had lower forearm
BMD, whereas those with TSH above the 97.5th percen-
tile had higher femoral neck BMD.
Although the current study was comprehensive, some
limitations remain.Datawere unavailable regarding prior
history of thyroid disease. Blood samples were from non-
fasting subjects. Although samples were taken at the same
time of day to mitigate effects of diurnal variation, espe-
cially in sCTX, it remains difficult to compare bone turn-
over results with other studies that used fasting early
morning specimens. During 6-yr follow-up, there were
only seven hip fractures, and so the association between
higher fT4 and incident hip fracture should be considered
with particular caution. Nevertheless, higher fT4 and fT3
werealsoassociatedwithan increased riskofnonvertebral
fracture, and higher TSH levels were protective. Overall,
the fracture data support the hypothesis that thyroid sta-
tus at the “hyperthyroid” end of the normal range is as-
sociated with an increased risk of nonvertebral fracture.
Established criteria for detection of vertebral fractures
were employed in this study (13, 18), and it is interesting
that there was no relationship between thyroid status and
vertebral fracture. This is consistent with a meta-analysis
of thyrotoxic patients that revealed only an increased risk
of hip fracture (40) andwith animal studies demonstrating
differential sensitivity to thyroid hormones at different
skeletal sites (23).
Overall, the current findings demonstrate that thyroid
status within the upper normal range in healthy euthyroid
postmenopausal women is associated with lower BMD
and an increased risk of nonvertebral fracture. Thus, thy-
roid status may be a physiological determinant of bone
maintenance and strength.
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Supplemental Table 1  Number of subjects in whom data was available for each variable 
 
Test variable Number 
  
Lumbar spine BMD at study entry 1272 
Hip BMD at study entry 1268 
Lumbar spine BMD at 6 years follow-up 789 
Hip BMD at 6 years follow-up 792 
TSH 1204 
FT4 1212 
FT3 1213 
Pulse rate 1244 
Balance 1240 
Grip strength 1085 
Osteocalcin 1217 
P1NP 1217 
sβCTX   1217 
uNTXCr 1214 
Incident vertebral fracture 474 
Incident hip fracture  365 
Incident non-vertebral fracture 401 
  
Supplemental Table 2  BMD in women with fT4 and fT3 in the lowest and highest quintiles 
 
 fT4 (mean ± SD) fT3 (mean ± SD) 
BMD (mg/cm2) Lowest quintile Highest quintile Lowest quintile Highest quintile 
 10.3 ± 0.9 pmol/L 15.6 ± 1.1 pmol/L 2.6 ± 0.3 pmol/L 4.9 ± 0.4 pmol/L 
     
Lumbar spine BMD (study entry) 1057±171 1018±164* 1047±161 1028±175 
Hip BMD (follow-up) 882±138 841±152* 881±146 862±152 
Lumbar spine BMD (study entry) 1062±177 1039±174 1025±160 1046±168 
Hip BMD (follow-up) 853±129 809±126* 863±139 819±129* 
Change in lumbar spine BMD -3.0±64.4 14.9±73.4 -14.4±57.5 14.9±72.1* 
Change in hip BMD -38.0±50.8 -47.4±47.8 -41.2±50.6 -47.9±49.7 
     
*P≤0.05 highest vs lowest quintile
Supplemental Table 3  Relationship between thyroid function, BMD, bone turnover and extra skeletal parameters 
 
 
fT4 (pmol/L) fT3 (pmol/L) TSH (mU/L) 
 Adjusted for age                         Adjusted for age  Adjusted for age  
 Model 
R2 
β coefficient              
95% CI  (lower, upper) p 
Mode
l R2 
β coefficient             
95% CI  (lower, upper) p 
Mode
l R2 
β coefficient              
95% CI  (lower, upper) p 
          
BMD:          
At study entry:          
Lumbar spine BMD  0.019 -0.044 (-9.456, 1.573) 0.161 0.018 -0.034 (-20.009, 5.492) 0.264 0.018 -0.035 (-13.740, 3.744) 0.262 
Hip BMD  0.136 -0.054 (-7.883, -0.021) 0.049 0.135 -0.036 (-15.716, 2.935) 0.179 0.134 0.008 (-5.505, 7.528) 0.761 
          
6 years follow-up:          
Lumbar spine BMD 0.004 -0.065 (-13.346, 1.369) 0.110 0.001 0.038 (-8.727, 24.752) 0.348 0.000 -0.011 (-19.267, 14.501) 0.782 
Hip BMD  0.126 -0.094 (-10.722, -1.699) 0.007 0.124 -0.081 (-23.655, -2.249) 0.018 0.122 0.064 (-0.349, 14.641) 0.062 
          
Change in lumbar spine 
BMD 
0.101 0.018 (-2.169, 3.503) 0.644 0.117 0.126 (4.493, 17.267) 0.001 0.101 0.005 (-6.067, 6.924) 0.897 
Change in hip BMD 0.008 -0.087 (-4.002, -0.344) 0.020 0.004 -0.053 (-7.534, 1.155) 0.150 0.005 0.058 (-0.598, 5.468) 0.115 
          
Bone turnover          
Osteocalcin 0.009 -0.027 (-0.450, 0.164) 0.362 0.008 -0.010 (-0.855, 0.602) 0.733 0.012 -0.063 (-1.079, -0.062) 0.028 
P1NP   0.000 0.007 (-0.508, 0.657) 0.802 0.000 -0.010 (-1.613, 1.147) 0.741 0.002 -0.046 (-1.745, 0.183) 0.112 
sβCTX   0.010 0.024 (-0.004, 0.010) 0.411 0.013 -0.060 (-0.035, -0.001) 0.037 0.012 -0.041 (-0.021, 0.003) 0.152 
uNTXCr  0.006 0.033 (-0.404, 1.426) 0.273 0.007 0.046 (-0.422, 3.914) 0.114 0.005 -0.019 (-2.015, 1.019) 0.520 
          
Extra skeletal parameters:          
At study entry:          
Pulse rate  0.004 0.031 (-0.135, 0.448) 0.292 0.010 0.08 (0.283, 1.660) 0.006 0.003 -0.011 (-0.580, 0.386) 0.694 
Grip strength 0.095 0.075 (0.041, 0.363) 0.014 0.119 0.172 (0.741, 1.494) <0.001 0.092 -0.040 (-0.450, 0.085) 0.182 
Balance 0.074 0.056 (0.000, 0.114) 0.053 0.080 0.099 (0.107, 0.379) <0.001 0.071 -0.021 (-0.132, 0.059) 0.454 
          
Statistically significant results in bold 
